Pilot Study of Pancreatic Cancer Screening
ConditionPancreatic Carcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco
About this trial
This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in BReast CAncer gene. (BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. This study may lead to a greater understanding of cancer and potentially, improvements in cancer screening and treatment.
Eligibility criteria
Qualifiers
Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM or PALB2 germline genetic mutation
No strong family history of pancreatic cancer (defined as having >= 1 first-degree or second-degree relative with a history of pancreatic cancer)
Age >= 50 years old at time of consent.
Documentation of pathogenic or likely pathogenic germline BRCA 1 and 2, ATM, or PALB2 germline genetic mutation
Disqualifiers
Prior or active pancreatic cancer.
Pregnant women are excluded from this study because effects of an MRI on developing fetus is unknown.
Trial design
Treatments tested in this trial
- Biospecimen Collection
- Magnetic Resonance Cholangiopancreatography
- Magnetic Resonance Imaging
- Endoscopic ultrasound
- Questionnaires
Treatment groups
250 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov